Spironolactone’s effect on blood sugar is surprisingly nuanced. The FDA label for Aldactone (brand-name spironolactone) does list hyperglycemia as a recognized metabolic abnormality, and periodic blood glucose monitoring is recommended. But the clinical research tells a more complicated story: a large meta-analysis found spironolactone raised HbA1c by a small amount (0.16%) while having no clear effect on fasting blood glucose, insulin levels, or insulin resistance. In practice, spironolactone’s impact on blood sugar is minimal for most people, especially compared to other diuretics.
What the FDA Label Says
The official prescribing information for spironolactone lists hyperglycemia alongside other metabolic abnormalities like high potassium and low sodium. The label recommends monitoring blood glucose periodically. However, no specific frequency for hyperglycemia is provided, which typically means it was uncommon enough in clinical trials and post-marketing reports that a reliable rate couldn’t be established.
What Clinical Studies Actually Show
A systematic review and meta-analysis of randomized controlled trials found that spironolactone raised HbA1c by an average of 0.16% in both men and women. To put that in context, HbA1c reflects your average blood sugar over roughly three months, and a shift of 0.16% is quite small. For someone with an HbA1c of 5.5%, this would move them to about 5.66%, still well within the normal range.
Importantly, the same meta-analysis found no significant effect on fasting glucose, fasting insulin, or HOMA-IR (a standard measure of insulin resistance). So while there’s a slight upward nudge in long-term blood sugar averages, the drug doesn’t appear to make your body less responsive to insulin or spike your blood sugar in a meaningful way on any given day.
Several individual studies in people with conditions like PCOS and high blood pressure have actually shown the opposite effect. In some trials, spironolactone at 100 mg daily decreased both insulin levels and insulin resistance over 3 to 12 months. One animal study using higher doses found reductions in blood sugar, insulin, triglycerides, and cholesterol. Lab research on human fat cells found that spironolactone increased glucose uptake into cells, a mechanism that would theoretically lower blood sugar rather than raise it. These beneficial effects weren’t consistent across all studies, though. In people with type 2 diabetes and kidney disease, for example, 50 mg daily had no effect on insulin or insulin resistance in either direction.
How It Compares to Other Diuretics
If you’re concerned about diuretics and blood sugar, spironolactone is actually one of the safer options. Thiazide diuretics, which are among the most commonly prescribed blood pressure medications, have a well-documented hyperglycemic effect. They raise blood sugar in a dose-dependent way, and the mechanism is tied to potassium loss: as potassium drops, insulin secretion from the pancreas is impaired, and blood sugar rises.
Spironolactone works differently. It’s a potassium-sparing diuretic, meaning it helps your body retain potassium rather than flush it out. Research comparing potassium-sparing diuretics to thiazides in hypertensive patients found that thiazides significantly worsened glucose tolerance while potassium-sparing diuretics did not. One older review concluded that spironolactone does not impair glucose tolerance even at high doses. This potassium-preserving quality may be a key reason spironolactone doesn’t cause the same blood sugar problems that thiazides do.
Effect When Combined With Diabetes Medications
For people taking both spironolactone and metformin, particularly women with PCOS, the combination doesn’t appear to cause problems. A meta-analysis looking at metformin plus spironolactone versus metformin alone found no significant increase in side effects from the combination. When treatment lasted six months or longer, the combination actually lowered fasting blood glucose and improved insulin resistance more than metformin alone. The reduction in fasting glucose was modest but statistically significant.
This suggests spironolactone doesn’t interfere with how diabetes medications work. If anything, it may complement them in certain populations over longer treatment periods.
Who Should Pay Attention
The small HbA1c increase from spironolactone is unlikely to matter for most people with normal blood sugar. But if your HbA1c is already borderline (in the 5.7% to 6.4% prediabetes range), even a 0.16% shift could nudge your lab results into a higher category on paper. This doesn’t necessarily mean the drug is causing diabetes, but it could complicate how your numbers are interpreted.
If you have type 2 diabetes and are monitoring your HbA1c closely, it’s worth knowing that spironolactone may contribute a small upward push that isn’t reflected in your daily fasting glucose readings. This discrepancy between HbA1c and fasting glucose has shown up consistently in the research, and the reason isn’t fully understood. One possibility is that spironolactone causes subtle changes in how long red blood cells survive or how glucose attaches to them, which would affect HbA1c without actually changing blood sugar levels.
The FDA’s recommendation to monitor blood glucose periodically while taking spironolactone is reasonable, especially for people already at risk for diabetes. But for the vast majority of people prescribed this medication, whether for blood pressure, heart failure, hormonal acne, or PCOS, a clinically significant rise in blood sugar is not a common concern.